Goldenwell Biotech, Inc.

Goldenwell Biotech, Inc. is an early-stage Nevada corporation focused on nutraceutical and dietary supplement products. The company currently has minimal operating history and no meaningful sales, and its near-term business is centered on raising capital and building out its initial commercial plan.

21,8 %

−539 038,2 %

−60,4 %

— Goldenwell Biotech, Inc.
%
Nutraceuticals50% Dietary and wellness-oriented products positioned between food and supplements.
Dietary supplements50% Vitamin, mineral, herbal, and other supplement products sold for health support.

The company appears to sell to consumers or distributors in the nutraceutical and dietary supplement market, but it has...

  • End consumersprimary

    Individuals buying nutraceuticals and dietary supplements for wellness and health support.

  • Retail and e-commerce channelssecondary

    Stores or online platforms that could carry the company's products as it commercializes.

  • Wholesale/distribution partnersemerging

    Intermediaries that may buy in bulk if the company develops a scalable product line.

Goldenwell Biotech is incorporated in Nevada and reports in U.S. dollars, indicating a U.S...

  • •Headquartered and incorporated in Nevada, United States
  • •Reports in U.S. dollars
  • •Occasional transactions in Chinese Renminbi
  • •Occasional transactions in Australian dollars
  • •No disclosed country revenue split

The company’s immediate strategy is to raise additional capital through debt or equity and use that funding to increase...

01
Capital raisingshort-term

The company needs external funding to continue operations and execute its business plan.

02
Product sales growthshort-term

Revenue is currently negligible, so commercial traction is required to validate the business model.

03
Business plan executionmedium-term

The company must convert its start-up structure into an operating business with repeatable demand.

Goldenwell Biotech faces substantial going-concern and financing risk because it has little operations, no meaningful...

critical

Going concern uncertainty

Management states the company needs financing to continue and attain profitable operations.

Scope
Little operations and recurring losses
Materiality
High
high

Capital raising failure

The plan depends on debt or equity offerings, but there is no assurance funding will be obtained.

Scope
Short-term liquidity and operating runway
Materiality
High
high

No meaningful revenue generation

The company reported $0 revenue in the recent quarter, limiting self-funding capacity.

Scope
Commercialization stage
Materiality
High
medium

Related-party funding concentration

A related-party loan is outstanding, indicating reliance on insider support.

Scope
Financing structure
Materiality
Medium
Going concern
Affects solvency assessment and investor confidence
Start-up expense recognition
Increases reported operating losses in early periods
Foreign currency translation
May create volatility in reported results
Fair value estimates
Affects balance sheet presentation and disclosure

NORTHWEST BIOTHERAPEUTICS INC

NWBO · Pharmaceutical Preparations

Ginkgo Bioworks Holdings, Inc.

DNA · Biological Products, (No Diagnostic Substances)

ANAPTYSBIO, INC

ANAB · Pharmaceutical Preparations

DYADIC INTERNATIONAL INC

DYAI · Biological Products, (No Diagnostic Substances)

MedWellAI, Inc.

MWAI · Finance Services

Solid Biosciences Inc.

SLDB · Biological Products, (No Diagnostic Substances)

: 28.4.2026